Cellectis SA (NASDAQ:CLLS)’s share price dropped 2.4% during mid-day trading on Thursday . The stock traded as low as $26.47 and last traded at $26.50, with a volume of 57,563 shares changing hands. The stock had previously closed at $27.14.

CLLS has been the topic of several recent research reports. Piper Jaffray Cos. reissued a “buy” rating on shares of Cellectis SA in a research note on Sunday, May 8th. Zacks Investment Research cut shares of Cellectis SA from a “hold” rating to a “sell” rating in a research note on Thursday, May 12th. Oppenheimer Holdings Inc. reissued a “buy” rating and issued a $65.00 price objective on shares of Cellectis SA in a research note on Monday, May 16th. Finally, Jefferies Group reissued a “buy” rating on shares of Cellectis SA in a research note on Friday, August 5th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. Cellectis SA currently has a consensus rating of “Buy” and an average price target of $43.60.

The firm has a 50-day moving average price of $26.55 and a 200-day moving average price of $26.99. The company’s market cap is $940.94 million.

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.